Cytokinetics CYTK Proceeds From Draw On RPI Multi Tranche Loan
Proceeds From Draw On RPI Multi Tranche Loan at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept cytk:ProceedsFromDrawOnRPIMultiTrancheLoan.
The official record: Cytokinetics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's proceeds from draw on rpi multi tranche loan.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's proceeds from draw on RPI multi tranche loan?
- Cytokinetics (CYTK) reported proceeds from draw on RPI multi tranche loan of $43.75M in Q4 2025.
- How has Cytokinetics's proceeds from draw on RPI multi tranche loan changed year-over-year?
- Cytokinetics's proceeds from draw on RPI multi tranche loan decreased by 12.5% year-over-year, from $50M to $43.75M.
- What is the long-term trend for Cytokinetics's proceeds from draw on RPI multi tranche loan?
- Over 2 years (2023 to 2025), Cytokinetics's proceeds from draw on RPI multi tranche loan has grown at a 87.1% compound annual growth rate (CAGR), from $50M to $175M.
- What does proceeds from draw on RPI multi tranche loan mean?
- Cash received from drawing on a specific multi-tranche loan facility.
- How do you interpret proceeds from draw on RPI multi tranche loan?
- Higher inflows indicate the successful achievement of milestones or the utilization of available credit lines to support R&D.
- How does proceeds from draw on RPI multi tranche loan compare across companies?
- Unique to biotech firms using royalty-based or milestone-linked financing structures.